REVB REVB
Company Profile ↓Company Overview
REVB (REVB) is a publicly traded company listed on with a market capitalization of $1.82M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -88.68% |
| 6 Months: | -31.14% |
| 3 Months: | +7.48% |
| 1 Month: | +16.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.18 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 90.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09M | 2.46M | 1.94M | 2.57M | 3.09M |
| Operating Income | - | - | - | -2.61M | -2.44M | -3.04M | -6.59M | -1.86M | -1.20M | -1.62M | -1.93M | -2.78M | -1.90M | -2.52M | -1.80M | - | -2.09M | -2.46M | -1.94M | -2.57M | -3.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.09M | -2.45M | -1.94M | -2.57M | -3.09M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.05M | -2.44M | -1.91M | -2.51M | -3.01M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.16K | -521 | -868 | -2.61M | -2.47M | -3.04M | -6.62M | -1.83M | -1.17M | 6.16M | -1.45M | -2.63M | -2.68M | -8.39M | -2.24M | - | -2.05M | -2.44M | -1.91M | -2.51M | -3.01M |
| Diluted EPS | - | - | - | - | -0.39 | -0.48 | -15.90 | -4.16 | -1.91 | 37.07 | -5.83 | -9.94 | -39.37 | -246.27 | -40.15 | - | -25.32 | -84.12 | -7.08 | -1.65 | -2.71 |
| R&D Expense | - | - | - | 1.56M | 1.16M | 1.53M | 3.68M | 975.58K | 381.57K | 525.27K | 909.28K | 1.65M | 717.58K | 1.39M | 830.98K | - | 858.83K | 1.32M | 922.86K | - | 1.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 10.86M | 8.66M | 7.98M | 9.07M |
| Operating Income | - | - | -11.95M | -10.86M | -8.66M | -7.98M | -9.07M |
| EBITDA | - | - | - | -10.84M | -8.63M | -7.95M | -9.04M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -10.83M | -120.25K | -15.04M | -8.91M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -3.64K | -1.63M | -11.99M | -10.83M | -120.25K | -15.04M | -8.91M |
| Diluted EPS | - | - | -42.50 | -91,775.84 | -101.28 | -1,052.16 | -23.95 |
| R&D Expense | - | - | 6.91M | 5.38M | 4.15M | 3.55M | 4.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 22.67K | 74.16M | - | 5.50M | 12.21M | 6.62M | 11.58M |
| Current Assets | - | - | - | 5.41M | 12.15M | 6.57M | 10.81M |
| Cash & Equivalents | - | 11.73K | - | 5.25M | 11.99M | 6.50M | 10.70M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | 26.31K | 6.34M | - | 4.45M | 5.56M | 1.91M | 2.72M |
| Current Liabilities | 26.31K | 3.43M | - | 4.45M | 5.56M | 1.91M | 2.00M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | 16.75K | 0 | - | 0 | 746.78K |
| Total Equity | -3.64K | 3.41M | - | 1.05M | 6.65M | 4.71M | 8.86M |
| Shares Outstanding | - | - | - | 118 | 1.38K | 43.52K | 1.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -216.66K | - | -11.22M | -7.29M | -18.32M | -8.27M |
| Investing Cash Flow | -74.04M | - | 0 | 0 | -19.17K | 0 |
| Financing Cash Flow | 74.26M | - | 15.20M | 14.03M | 12.85M | 12.47M |
| Capital Expenditure | - | -131.96K | - | - | -19.17K | - |
| Free Cash Flow | - | - | -11.22M | -7.29M | -18.34M | -8.27M |
| Net Change in Cash | - | - | 3.98M | 6.74M | -5.49M | 4.20M |
| Share Buybacks | - | 35.50M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 100.0% | -47.8% | - | -1,029.0% | -1.8% | -319.4% | -100.6% |
| ROCE % | - | - | - | -1,032.3% | -130.2% | -169.4% | -94.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for REVB
REVB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5PZVR4eW9KZnpyMnl5RUlTTFVZZ3lCRXA2c3F1V0diVGJndS1sRVZkR3paWmNJV2JCV2pqaEh0QTFlekJOR0NGR1lqWmZzZEZBRXlMTHhNMDlaWkM0djFhQ1ZheTNuZDBfWlZCakEzNFU3UlI3Z1dPODBn?oc=5" target="_blank">REV…
REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNcXRKUWVCZlpwYzFyS1YyRUxSb0RDTmpMM2pHLTNLb2RhM1B4cG5KdmQxT2NWTmpzVXJSVFRHTUhURVNhUWJYemRlcmpJSXZVeW5yWk1CWkx2OU5GR1U1QU5BRGF1eHF2TENSNm1qZ0VZTWhsRUxvOWpFY1Y3UkhHOUpncEpMc1lQMlZEbT…
REVB|Revelation Biosciences Inc|Price:1.070|Chg%:+0.032 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBxT0h6bEFoZ201cklMNGMxWDl3R0djeTJ4SkI1VXFTZ0U3X0lKaTJJemh1d0wyajZiemdDQlNCbVJyNkhSVGZKOGg1UVM4ckpnMWdyWVVqVUN2SmFCMk1ZR1BQOVhmWXZ4dU1qaHVR?oc=5" target="_blank">REVB|Revelation Bio…
Revelation Biosciences (NASDAQ:REVB) secures FDA agreement setting single-study path for kidney drug Gemini - Kalkine
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPZWRXZzR5M2FsaEd5a29Lbi1ISkxCRFlBWWtIWWV1VHBwTHAzeGhvNkJXZjRIY2NUdnp0UmdMQm1vS09CM3ZTN1BIT29Ua25KRG92WHl3SVcyMXRla29oY3dTVUlEWEtUZzFheFVRRTFnbDRUZ240ZUY3NGR0aEZxVi10QXBDLWZIQXdWYW…
Revelation Biosciences Inc. (REVB) Holds Steady at $1.15 as Consolidation Continues - Sentiment Shift - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQa3RyVjdPVmxFQV8zQ1JXQzZmZ3VlbGYxYXV5cDE0RDd4c3lZSlBWR2lGYVVDZ3pwQ1oweXoyU2huYlZUMnJtWGJtLXpUNEZkUTZ5YlRTN0hyUlRUNmliNXRxdXd0Y0NOUFNoaTNjbV9Wd0l0T2RwY1lGQ0xvTXpabVpIcUc0cnhieEc3SG…
Revolution Beauty Group plc Revenue Breakdown – LSE:REVB - TradingView
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE5CeldDTUVMTk1aajZGWG1XN0szcENyNWx5eFhzQTFEdlZsNURrZkFSUVh4bzFZQ0hEX3luckZueVhVU0I4bnJkSS12Wk41VnVpYW1NdGl2Mkg4ZmZ5UU5zYVZlcTFrQVFLaWRMOXJwRGl2RzA?oc=5" target="_blank">Revolution B…
REVB — Frequently Asked Questions
What is the current share price of REVB?
As of 2026-08-05 17:25 PDT, REVB trades at $1.15 on NASDAQ/NYSE. Its 52-week range is $0.95 to $11.72.
What is the market capitalisation of REVB?
REVB has a market capitalisation of $1.82M on NASDAQ/NYSE.
What is the P/E ratio of REVB?
REVB trades at a trailing price-to-earnings (P/E) ratio of -0.05. Its price-to-book (P/B) ratio is 0.21.
What is the return on equity (ROE) of REVB?
REVB has a return on equity (ROE) of -100.59%. Its return on capital employed (ROCE) is -94.64%.
Is REVB a good stock to buy?
This page provides a data-driven analysis of REVB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.